NBI-1070770 for Depression
Trial Summary
What is the purpose of this trial?
To evaluate the efficacy, safety, and tolerability of NBI-1070770 compared to placebo on improving symptoms of depression in participants with major depressive disorder (MDD).
Will I have to stop taking my current medications?
No, you will not have to stop taking your current antidepressant medications. Participants must continue with their current antidepressant medication(s) during the trial.
What makes the drug NBI-1070770 unique for treating depression?
Research Team
Clinical Development Lead
Principal Investigator
Neurocrine Biosciences
Eligibility Criteria
This trial is for adults with recurrent or persistent Major Depressive Disorder (MDD) who've been on their current antidepressants for at least 8 weeks. They must be willing to continue these meds and follow all study rules.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive NBI-1070770 or placebo to assess efficacy, safety, and tolerability in improving symptoms of depression
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- NBI-1070770
Find a Clinic Near You
Who Is Running the Clinical Trial?
Neurocrine Biosciences
Lead Sponsor
Kyle W. Gano
Neurocrine Biosciences
Chief Executive Officer since 2024
PhD in Pharmacology
Dr. Sanjay Keswani
Neurocrine Biosciences
Chief Medical Officer
MD